| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-65906-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB8327 | |||
| Carrier Free | MAB8327-SP | |||
| Carrier Free | FAB8327V-100UG | |||
| Carrier Free | FAB8327U-100UG | |||
| Carrier Free | FAB8327T-100UG | |||
| Carrier Free | FAB8327S-100UG | |||
| Carrier Free | FAB8327R-100UG | |||
| Carrier Free | FAB8327N-100UG | |||
| Carrier Free | FAB8327G-100UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22116 | |||
| BSA Free | NBP2-22116SS | |||
| Azide and BSA Free | NBP2-80689 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB114F | |||
| Carrier Free | FAB114A | |||
| Carrier Free | FAB114V-025 | |||
| Carrier Free | FAB114N-100UG | |||
| Carrier Free | FAB114G-100UG | |||
| Carrier Free | FAB114U-100UG | |||
| Carrier Free | FAB114T-100UG | |||
| Carrier Free | FAB114S-100UG | |||
| Carrier Free | FAB114R-025UG | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | FAB114F | |||
| Carrier Free | FAB114A | |||
| Carrier Free | FAB114V-025 | |||
| Carrier Free | FAB114N-100UG | |||
| Carrier Free | FAB114G-100UG | |||
| Carrier Free | FAB114U-100UG | |||
| Carrier Free | FAB114T-100UG | |||
| Carrier Free | FAB114S-100UG | |||
| Carrier Free | FAB114R-025UG | |||
![Flow Cytometry: CD45 Antibody (YKIX716.13) [NB100-65906] - Staining of canine peripheral blood lymphocytes with rat anti-canine CD45 antibody (YKIX716.13) [NB100-65906], using F(ab')2 rabbit anti rat IgG: FITC (STAR17B) as a secondary antibody.](http://images.novusbio.com/fullsize/CD45-Antibody-YKIX716-13-Flow-Cytometry-NB100-65906-img0001.jpg "Flow Cytometry: CD45 Antibody (YKIX716.13) [NB100-65906] - Staining of canine peripheral blood lymphocytes with rat anti-canine CD45 antibody (YKIX716.13) [NB100-65906], using F(ab')2 rabbit anti rat IgG: FITC (STAR17B) as a secondary antibody.")
![Flow Cytometry: CD45 Antibody (YKIX716.13) [NB100-65906] - Immunophenotyping & multipotency assay. Representative dot plots from flow cytometry analysis (A). Expression of surface antigens were investigated in cells cultured in control & AZA/RES supplemented medium. Isolated cells were characterized by the expression of CD90 & CD44 while lacked the expression of CD45 hematopoietic marker (B). Multipotency of isolated cells was confirmed by three lineage differentiation (C). In order to confirm formation of proteoglycans during chondrogenesis cells were stained with Safranin O. Intracellular lipid droplets were visualized by Oil Red O while mineralized matrix formed during osteogenesis with Alizarin Red. Magnification ×100, scale bars: 250 μm. Results expressed as mean ± SD. Statistical significance indicated as asterisk (*) when comparing the result to ASCCTRL, & as hashtag (#) when comparing to ASCEMS. ###P < 0.001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30370650), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-65906_rat-monoclonal-cd45-antibody-ykix716-13-31020241612693.jpg)